

# Yukihisa Fujinaga

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8331207/yukihisa-fujinaga-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31  
papers

141  
citations

7  
h-index

9  
g-index

41  
ext. papers

254  
ext. citations

4.1  
avg, IF

2.34  
L-index

#	Paper	IF	Citations
31	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.. <i>Indian Journal of Gastroenterology</i> , <b>2022</b> , 41, 169	1.9	1
30	Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy.. <i>In Vivo</i> , <b>2022</b> , 36, 1477-1484	2.3	
29	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , <b>2021</b> , 21, 30	2.1	
28	Comparison of the efficacy and safety between palliative biliary stent placement and duct clearance among elderly patients with choledocholithiasis: a propensity score-matched analysis. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 369	3	
27	Efficacy of Underwater Endoscopic Mucosal Resection for Superficial Non-Ampullary Duodenal Epithelial Tumor. <i>Clinical Endoscopy</i> , <b>2021</b> , 54, 371-378	2.5	7
26	Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	5
25	The association of histological progression with biochemical response to ursodeoxycholic acid in primary biliary cholangitis. <i>Hepatology Research</i> , <b>2021</b> , 51, 31-38	5.1	2
24	The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis. <i>Medicine (United States)</i> , <b>2021</b> , 100, e27212	1.8	2
23	Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis. <i>Medicine (United States)</i> , <b>2021</b> , 100, e27403	1.8	0
22	Accuracy of Fibrosis-4 Index in Identification of Patients with Cirrhosis Who Could Potentially Avoid Variceal Screening Endoscopy. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	5
21	Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
20	Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	7
19	Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study. <i>Hepatology Research</i> , <b>2020</b> , 50, 1101-1105	5.1	3
18	Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis. <i>Microorganisms</i> , <b>2020</b> , 8,	4.9	10
17	Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	6
16	Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites. <i>Experimental and Therapeutic Medicine</i> , <b>2020</b> , 21, 1-1	2.1	
15	Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 7232-7241	5.6	3

14	Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia. <i>Digestive Diseases</i> , <b>2020</b> , 38, 329-334	3.2	3
13	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	8
12	Effect of furosemide on muscle cramps in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 76-81	4	4
11	Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. <i>Antibiotics</i> , <b>2020</b> , 9,	4.9	13
10	Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	3
9	TGR5 Activation Modulates an Inhibitory Effect on Liver Fibrosis Development Mediated by Anagliptin in Diabetic Rats. <i>Cells</i> , <b>2019</b> , 8,	7.9	6
8	Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis. <i>Hepatology Research</i> , <b>2019</b> , 49, 1147-1161	5.1	4
7	Identification of clinical risk factors for histological progression of primary biliary cholangitis. <i>Hepatology Research</i> , <b>2019</b> , 49, 1015-1025	5.1	7
6	Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. <i>World Journal of Gastrointestinal Oncology</i> , <b>2019</b> , 11, 887-897	3.4	1
5	Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. <i>Hepatology Research</i> , <b>2019</b> , 49, 232-238	5.1	4
4	Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis. <i>Hepatology Research</i> , <b>2019</b> , 49, 284-295	5.1	15
3	Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection. <i>Experimental and Therapeutic Medicine</i> , <b>2018</b> , 16, 2743-2750	2.1	4
2	Glycogenic Hepatopathy in Type 1 Diabetes Mellitus. <i>Internal Medicine</i> , <b>2018</b> , 57, 1087-1092	1.1	6
1	Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis. <i>Hepatology Communications</i> , <b>2017</b> , 1, 928-945	6	8